Page 16 - Base Case News Today

Redeye raises its Base Case and forecasts slightly following the Q1 report. Although transaction revenue saw a greater impact from the macroeconomic slowdown than we expected, the net customer intake... | May 2, 2023

SP Angel. Morning View. Tuesday 02 05 23 Lithium carbonate rises to $23,344/t on sustained EV demand   MiFID II exempt information – see disclaimer below...

Inside the Market’s roundup of some of today’s key analyst actions

TORONTO--(BUSINESS WIRE)--$MIMZF #gold--Nighthawk Gold Corp. (“Nighthawk”, “NHK”, or the “Company”) (TSX: NHK; OTCQX: MIMZF) is pleased to report its maiden PEA1 for the Colomac Gold Project, located

Investegate announcements from MC Mining Limited, Makhado Project Update

Results of the preliminary economic assessment1 for the Colomac Gold Project suggest the potential for a C$1.2 billion after-tax net present value @ 5% discount rate and 35% after-tax internal... | April 26, 2023

Lives in maine. it is dying off at an alarming rate. like how is that? not on the front page of like every newspaper every day like breathing is awesome. i like doing it. and so to save the plankton that gives us breath. marty hopes his bowie is a breakthrough. a new science called artificial ocean alkaline ization. which would demand a lot of limestone. so the base case is like, okay, we take 2.5 mount fujis of limestone. but thats the volume 2.5 mount foodies. and dissolve that into the very t...

Acidification is kind of the most terrifying thing i can possibly imagine to happen to the world. you know, 50% of our oxygen comes out of from phytoplankton. and where marty lives in maine. it is dying off at an alarming rate. like how is that? not on the front page of like every newspaper every day like breathing is awesome. i like doing it. and so to save the plankton that gives us breath. marty hopes his bowie is a breakthrough. a new science called artificial ocean alkaline ization. which w...

There is news from ARK Invest that Tesla has a base case price target of $2,000 in 4 years. Here's why.

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision after the recent Q1... | April 21, 2023